Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07096778Phase 2Recruiting

Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT04068597Phase 1Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Role: lead

NCT06322927Completed

PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

Role: collaborator

NCT03568656Phase 1Completed

Study to Evaluate CCS1477 in Advanced Tumours

Role: lead

All 4 trials loaded